RATIONALE: Regular peanut consumption after immunotherapy may provide continued protection against accidental exposures, however limited data exists regarding its long-term safety. METHODS: Past participants in peanut immunotherapy trials were enrolled in a longitudinal observational study. Those desensitized to > _300mg of peanut were instructed to incorporate dietary peanut. We reviewed peanut food equivalent dosing and associated reactions in 55 subjects who completed oral (OIT) or sublingual immunotherapy (SLIT) studies between 2010-2017. RESULTS: The majority of subjects were male (55%), Caucasian (94%), and participated in an OIT trial (73%). Peanut consumption was continued in 49/55 (89%) subjects. Adverse reactions, including EoE in one subject, and taste aversion were causes for discontinuation. Median peanut consumed was 600 mg (mean 808 mg, 100-4800 mg). Thirty-one subjects (74%) consumed peanut daily. Lower peanut consumption correlated with older age (r 5 -0.17). Ten (23.8%) subjects reported reactions with urticaria, gastrointestinal symptoms, and oropharyngeal pruritus, the most common. The majority of reactions were treated with antihistamines; however 1 reaction required epinephrine and 2 required EMS. There was no correlation between peanut dose and reactions. Participants in SLIT trials consumed less peanut (median 500 mg, mean 543 mg) compared to OIT participants (median 600 mg, mean 955 mg); however more reactions with dosing were reported with OIT (7/10). CONCLUSIONS: The majority of subjects continued dietary peanut up to 8 years after study completion. Food equivalents may be a safe option for maintaining desensitization. Further study is needed to understand the impact of age and types of immunotherapy on peanut consumption and reactions. RATIONALE: Almond, a popular tree nut, can cause IgE-mediated allergic reactions. Almond flour from various vendors are often contaminated with high levels of microbes. Irradiation is a method that can decrease bioburden, however, irradiated almond flour used in oral immunotherapy (OIT) trials has not been characterized. We aimed to quantify relative amounts of the major almond allergen (Pru du 6) and bioburden levels present in irradiated almond flour used in OIT trials and assess whether these parameters are stable. METHODS: SDS-PAGE gels and densitometric analysis of Pru du 6 were used to assess allergen content in almond flour exposed to gamma irradiation (Minimum/Maximum Dose of 5.0kGy -30.0kGy). Bioburden testing was conducted on two different lots of irradiated almond flour for the presence of Escherichia coli, salmonella, yeast, mold, and total aerobic bacteria. RESULTS: Relative amounts of the major almond allergen (Pru du 6) was similar between the two different lots of irradiated almond flour and remained stable over a twelve month period (with a variance of <10%). E coli and salmonella were absent from both lots of irradiated flour. Yeast, mold, and total aerobic bacteria were within established US Pharmacopeia guidelines on both lots tested and remained within the criteria over a period of twelve months. CONCLUSIONS: Irradiated almond flour used as a drug product contains the major almond allergen and has low bioburden levels. Both these parameters remain stable over a 12-month period and met criteria established by FDA for an orally delivered drug product. 8 Aimmune Therapeutics, Brisbane, CA, 9 Emory University School of Medicine, Atlanta, GA. RATIONALE: RAMSES, a phase 3, multicenter, randomized, doubleblind, placebo-controlled, real-world safety study of AR101 (an investigational oral biologic drug used in oral desensitization immunotherapy), used readily available clinical data to identify eligible participants. We sought to compare baseline characteristics of participants in RAMSES to those from PALISADE, a phase 3 trial of AR101, which in addition to clinical data, utilized a screening double-blind, placebo-controlled food challenge (DBPCFC) to determine eligibility. METHODS: RAMSES enrolled participants ages 4-17-years-old in North America with a physician-confirmed diagnosis of peanut allergy, skin prick test (SPT) mean peanut wheal diameter > _8mm, and peanut sIgE > _14kUA/ L. PALISADE enrolled participants based on clinical history, SPT mean peanut wheal diameter > _3mm and/or peanut sIgE > _0.35kUA/L, and reaction at screening DBPCFC. Summary statistics for baseline characteristics are compared between RAMSES and PALISADE participants 4-17-years-old. RESULTS: Subjects in both studies (RAMSES N5505; PALISADE, N5496) were predominantly male (63.4%; 57.3%) and Caucasian (78.2%; 78.4%) with a median age of 9-years (both trials). Atopic comorbid disease frequencies were comparable between trials: allergic rhinitis (74.5%; 71.8%), atopic dermatitis (59.2%; 62.1%), other food allergies (52.7%; 65.5%), and asthma (49.5%; 52.8%). Peanut sIgE (median [IQR]: 93.5kUA/L [42.8, 201.0]; 71.3kUA/L [19.7, 202.0]) and SPT wheal diameter (median 13.5mm [10.5, 19.0]; 11.0mm [9.0, 15.0]) were similar. CONCLUSIONS: Baseline characteristics appeared similar in RAMSES and PALISADE participants, despite the former study not requiring a DBPCFC. This suggests that it is feasible to identify potentially eligible peanut-allergic individuals with the use of readily available clinical data, which aligns with routine clinical practice. 
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